Agilon Health (AGL) Could Be 54% Above Fair Value As CTO Exit Raises Questions

agilon health (AGL) drew investor attention after announcing that Chief Technology Officer Girish Venkatachaliah will leave his role on August 1, 2026, and will remain as a consultant through the end of the year.

See our latest analysis for agilon health.

The CTO transition comes at a volatile moment for agilon health, with the share price falling 6.54% over the last day and 22.71% over the last week, yet still showing a very large year to date share price return of around 4.5x and a 94.05% total shareholder return over the past year, even as the 3 year and 5 year total shareholder returns remain deeply negative.

If this executive change has you thinking about how other healthcare technology stories are priced, it could be a good time to scan 41 healthcare AI stocks.

agilon health now sits at the crossroads of a fast growing senior care platform and a share price that has already delivered very large gains. After this sharp pullback, is the business quality still aligned with what investors are paying for it today?

Most Popular Narrative: 53.5% Overvalued

agilon health closed at $92.66, while the most followed fair value narrative sits at $60.36. That gap is where the story gets interesting.

The accelerating growth of the senior population and increasing prevalence of complex, chronic conditions, especially among the 80+ age group, are fueling multi-year demand for agilon health's model focused on comprehensive, value-based primary care for seniors. This demographic shift is expected to materially expand patient volumes and recurring revenues over time.

Read the complete narrative.

Analysts behind this narrative are tying that demographic wave to a specific path for revenue growth, a swing from losses to profits, and a richer future earnings multiple. Curious which assumptions need to hold for agilon health to grow into that $60.36 fair value while today’s price sits much higher?

Result: Fair Value of $60.36 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, agilon health still faces execution risk around payer renegotiations and Medicare Advantage membership trends. These factors could challenge the optimistic revenue and margin assumptions behind this narrative.

Find out about the key risks to this agilon health narrative.

Another View on agilon health’s Valuation

The analyst narrative points to agilon health being 53.5% overvalued at $92.66 versus a $60.36 fair value. Yet Simply Wall St’s DCF model presents a different picture, with a future cash flow value estimate of $395.41 that suggests the stock trades far below that level.

If those two signals are pulling you in opposite directions, it comes down to which assumptions on growth, margins, and risk you trust more, and how much valuation gap you are comfortable with.

Look into how the SWS DCF model arrives at its fair value.

Next Steps

With agilon health attracting both cautious and optimistic views, it may be useful to take a closer look and review the numbers yourself. The company presents a combination of flagged risks and potential rewards that you can evaluate on your own terms through the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond agilon health?

If you want to stress test your thinking after reviewing agilon health, use the Simply Wall St screener to quickly spot other opportunities that match your style.

• Target long term value by scanning companies that combine quality fundamentals with attractive prices through the 49 high quality undervalued stocks.
• Prioritise resilience and sleep easier at night by reviewing companies highlighted in the 85 resilient stocks with low risk scores.
• Hunt for early stage potential by checking the 20 elite penny stocks with strong financials before the next idea gains wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com